When pursuing breakthrough ideas ("10x thinking"), the process is inherently uncomfortable. It's crucial to distinguish this discomfort, which signals you're pushing boundaries, from the feeling of being wrong. Embracing this discomfort is key to innovation in ambiguous, early-stage product development.

Sana CEO Steve Harr actively questions whether the company's groundbreaking science can translate into a scalable, commercially viable therapy. This internal pressure focuses the team on solving not just the scientific challenges ("does it work?"), but also manufacturing ("can you scale it?") and the commercial model required for a true cure.

True innovation requires leaders to adopt a venture capital mindset, accepting that roughly nine out of ten initiatives will fail. This high tolerance for failure, mirroring professional investment odds, is a prerequisite for the psychological safety needed for breakthrough results.

While scientific acumen is valuable, the most critical trait for a biotech CEO is perseverance. The role involves weathering constant challenges where everyone—the board, investors, employees—can seem to be against you. An unwavering focus on the patient mission is essential to push through.

A founder must simultaneously project unwavering confidence to rally teams and investors, while privately remaining open to any evidence that they are completely wrong. This conflicting mindset is essential for navigating the uncertainty of building a startup.

Jeremy Levin urges biotech leaders to be bold, defining it as 'disciplined courage.' This means choosing important, non-fashionable science over me-too drugs (e.g., another PD-1), building companies for long-term patient impact rather than a quick sale, and vocally defending the institutions that enable innovation, even when it's uncomfortable.

Solving truly hard problems requires a form of 'arrogance'—an unwavering belief that a solution is possible, even after months or years of failure. This 'can-do' spirit acts as an accelerator, providing the persistence needed to push through challenges where most would give up.

True scientific advancement happens when researchers refuse to accept 'no' as an answer. When immunotherapy was dismissed for lung cancer, pioneers investigated why it worked in melanoma but not other cancers. This mindset—questioning failures and studying successes—is key to turning scientific impossibilities into standard treatments.

A critical mindset shift from academia to startups is embracing the "killer experiment." Academics may fear an experiment that disproves a long-held hypothesis. In contrast, biotech startups, with finite capital, must run these experiments early to either validate or kill a program, efficiently allocating resources to viable projects.